EPO and Huntington disease: 86 adult HD patients, already on SC EPO-alfa treatment, were switched simultaneously to IV EPO-alfa, at the same weekly dose as their SC administration, for a period of 6 months. Monthly Red cell indices, weekly EPO dosages and other parameters were monitored during the study.